A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.
A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.
HR 7667, also known as the Biosimilar User Fee Amendments of 2022, was introduced by Representative Anna Eshoo (D-California) and Health Subcommittee Ranking Member Brett Guthrie (R-Kentucky). It was referred to the House Committee on Energy and Commerce. According to Bloomberg Law, the committee voted 30-0 to advance the measure.
“This legislation would reauthorize FDA’s user fee programs, which are critically important to ensure the agency has the funding it needs so that Americans can continue to trust that the drugs and medical devices they use are safe and effective…. This comprehensive package also includes important provisions that will help lower drug costs for the American people by promoting competition,” said Energy and Commerce Committee Chairman Frank Pallone, Jr (D-New Jersey) during his opening remarks at a Health Subcommittee markup of 6 bipartisan bills, including HR 7667.
User fee programs for biosimilars, as monitored under the Biosimilar User Fee Act, are used to support the review of biosimilar product applications, including hiring staff, improving systems, and maintaining a well-managed program to optimize patient access to these medications. User fees are collected from applications and the FDA is responsible with ensuring that they are sufficient to cover expenses.
When the COVID-19 pandemic hit, the FDA was looking to revise its methodology for determining the needs for its human drug and biosimilar biologic review programs. A major problem with these programs was that unexpected workload increases did not result in comparable increased in user fees collected from manufacturers who submitted applications for new drugs to be reviewed, leading to the FDA experiencing a funding shortfall.
“The Food and Drug Administration’s user fee agreements allow the agency to fulfill its mission to review and approve the medications that Americans rely on…. As we continue to face the COVID-19 pandemic, adequate funding and staffing levels at FDA are more important than ever. Patients rely on FDA’s gold standard of safety and efficacy, and the American people are relying on us to ensure the agency has the resources it needs to improve development, review applications, and monitor drug safety in a timely manner,” said Eshoo in a statement.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.